Association ofABCB1C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy
Authors:
- 4 April 2015
- journal article
- research article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 40 (3) , 315-319
Abstract
One-third of patients with epilepsy are resistant to anti-epileptic drugs (AEDs). Drug-resistant epilepsy is believed to be multifactorial involving both genetic and non-genetic factors. Genetic variations in the ABCB1 gene encoding the drug efflux transporter, p-glycoprotein (p-gp), may influence the interindividual variability in AED response by limiting drugs from reaching their target. Phenobarbital (PB), one of the most cost-effective and widely used AEDs in developing countries, has been reported to be transported by p-gp. This study aimed to investigate the association of a genetic variant, ABCB1 3435C>T, and non-genetic factors with phenobarbital response in Thai patients with epilepsy. One hundred and ten Thai patients with epilepsy who were treated with PB maintenance doses were enrolled in this study. Two phenotypic groups, PB-responsive epilepsy and PB-resistant epilepsy, were defined according to the International League Against Epilepsy (ILAE) criteria. Subjects were genotyped for ABCB1 3435C>T (rs1045642). Multiple logistic regression analysis was tested for the association of ABCB1 3435C>T polymorphism and non-genetic factors with PB response. Sixty-two PB-responsive epilepsy subjects and 48 PB-resistant epilepsy subjects were identified. All genotype frequencies of the ABCB1 3435C>T SNP were consistent with the Hardy-Weinberg equilibrium (P > 0·05). The ABCB1 3435C>T polymorphism and type of epilepsy were associated with response to PB. Patients with PB-resistant epilepsy had a significantly higher frequency of ABCB1 3435CC genotype and had focal epilepsy more often than patients with PB-responsive epilepsy (adjusted OR = 3·962, 95% CI = 1·075-14·610, P-value = 0·039; adjusted OR = 5·936, 95% CI = 2·272-15·513, P-value < 0·001, respectively). The model explained 25·5% of the variability in response to PB (R(2) = 0·255). Thai patients of ABCB1 3435CC genotype and with focal epilepsy were more often PB resistant. Those two factors partly account for the variability in Thai epilepsy patients' response to phenobarbital.Keywords
Funding Information
- Chulalongkorn University
- Faculty of Pharmaceutical Sciences
- Ratchadaphiseksomphot Endowment Fund
- Pharmaceutical Sciences Research Fund
This publication has 40 references indexed in Scilit:
- Standards for epidemiologic studies and surveillance of epilepsyEpilepsia, 2011
- Multidrug‐resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: Data from international pharmacogenetic cohortsEpilepsia, 2009
- Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han ChineseEpilepsy & Behavior, 2007
- ABCB1 Polymorphisms Influence the Response to Antiepileptic Drugs in Japanese Epilepsy PatientsPharmacogenomics, 2006
- Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug TreatmentEpilepsia, 2005
- Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable EpilepsyEpilepsia, 2005
- Phenobarbital for the Treatment of Epilepsy in the 21st Century: A Critical ReviewEpilepsia, 2004
- Mechanisms of antiepileptic drug resistanceCurrent Opinion in Neurology, 2003
- P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in ratsNeuroscience Letters, 2002
- Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProceedings of the National Academy of Sciences, 2000